MACROGENICS INC

MGNX

Held by 8 specialist biotech funds

High ConvergenceHigh short interest · No specialist buying

8 funds opened new positions. Next phase3 readout (Margetuximab): Aug 2021. Short interest: 11.4% of float.

Catalysts

Phase 2NegativeQ1 2009RAV12Pancreatic CancerNCT00625586

Primary: Number of Patients Alive at 8 Months (8 months)Enrollment:2/2Sites: 2NA, TREATMENT

Phase 3PositiveQ2 2010TeplizumabType 1 Diabetes MellitusNCT00385697

Primary: Number of Subjects in Segment 2 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and Hemoglobin A1c (HbA1c) Level of Less Than 6.5%. (52 weeks after randomization)Enrollment:554/554Sites: 115RANDOMIZED, TRIPLE, TREATMENT

Phase 2NegativeQ1 2011MGAWN1West Nile Neuroinvasive Disease, West Nile Virus Infection, EncephalitisNCT00927953

Primary: The Number of West Nile Neuroinvasive Disease (WNND) Participants Who Show Improvement in the Modified Rankin Scale (MRS) (>=1 Improvement in Score) (Study Day 2, 7, 14, 28, and 120)Enrollment:13/13RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ4 2016MargetuximabBreast CancerNCT01828021

Primary: Best Overall Response (Cycle 2, Day 21)Enrollment:25/25Sites: 6NA, TREATMENT

Phase 3Q4 2020enoblituzumabHead and Neck Cancer, Squamous Cell Carcinoma of Head and NeckNCT04129320

Primary: Overall Response Rate (Modules X and Y) (2 years)0NON_RANDOMIZED, TREATMENT

Phase 3PositiveQ3 2021MargetuximabHER-2 Positive Breast Cancer, Metastatic NeoplasmNCT02492711

Primary: Progression-free Survival (PFS) as Determined by Independent Radiological Review. (Tumor assessments are conducted every 6 weeks for the first 24 weeks and then every 24 weeks until progression of cancer, average 5 months.)Enrollment:624/624Sites: 167RANDOMIZED, TREATMENT

Phase 2NegativeQ3 2022Flotetuzumab 3 ng/kg/day, 4 days on and 3 days offAMLNCT02152956

Primary: Efficacy Based on CR or CRh Rate (up to 14 months)Enrollment:244/244Sites: 43NON_RANDOMIZED, TREATMENT

Phase 2NegativeQ3 2022EnoblituzumabHead and Neck Cancer, Head and Neck Neoplasms, Head and Neck Squamous Cell CarcinomaNCT04634825

Primary: Overall Response Rate (ORR) of Enoblituzumab Plus Retifanlimab (Tumor assessment is conducted 6 weeks after the first dose, then every 9 weeks until disease progression, up to 16.5 months.)Enrollment:62/62Sites: 42NON_RANDOMIZED, TREATMENT

Phase 2NegativeQ1 2023vobramitamab duocarmazineSquamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, MelanomaNCT03729596

Primary: Number of Patients With Adverse Events of Vobramitamab Duocarmazine as Assessed by CTCAE v4.03 (Throughout the study up to 24 months)Enrollment:143/143Sites: 21NON_RANDOMIZED, TREATMENT

Phase 3Q1 2024margetuximabGastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric CancerNCT04082364

Primary: Number of Participants With Adverse Events of Margetuximab Plus Retifanlimab in Cohort A, as Assessed by CTCAE v5.0 (Throughout the study, an average of 11 months.)Enrollment:82/82Sites: 73RANDOMIZED, TREATMENT

Phase 2Q1 2026lorigerlimabAndrogen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Prostate Cancer RecurrentNCT05848011

Phase 2Q3 2027LorigerlimabPlatinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal CarcinomaNCT06730347

MACROGENICS INC

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Activist Filings

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research